Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

Classic congenital adrenal hyperplasia, more commonly called classic CAH, is when there is an enzyme missing in the adrenal gland, which causes the body to have the inability to make enough cortisol.

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

Sexual precocity and a testicular mass can result from a Leydig cell tumor or from simple virilizing CAH with adrenal rests in the testes. These diagnoses are usually distinguished by very high ...

HBM Alpha Therapeutics has signed a collaboration and licensing agreement, granting an unnamed business partner exclusive ...

Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for the rare disorder that works by directly targeting the underlying ...